ProfileGDS4814 / ILMN_1755937
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 87% 88% 90% 87% 87% 90% 89% 87% 89% 90% 87% 89% 90% 89% 89% 90% 89% 89% 86% 88% 87% 86% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)280.40187
GSM780708Untreated after 4 days (C2_1)309.65888
GSM780709Untreated after 4 days (C3_1)395.13690
GSM780719Untreated after 4 days (C1_2)271.94287
GSM780720Untreated after 4 days (C2_2)284.31287
GSM780721Untreated after 4 days (C3_2)409.44690
GSM780710Trastuzumab treated after 4 days (T1_1)350.03389
GSM780711Trastuzumab treated after 4 days (T2_1)294.99287
GSM780712Trastuzumab treated after 4 days (T3_1)350.41189
GSM780722Trastuzumab treated after 4 days (T1_2)394.76990
GSM780723Trastuzumab treated after 4 days (T2_2)302.60787
GSM780724Trastuzumab treated after 4 days (T3_2)353.21389
GSM780713Pertuzumab treated after 4 days (P1_1)394.59590
GSM780714Pertuzumab treated after 4 days (P2_1)382.70589
GSM780715Pertuzumab treated after 4 days (P3_1)382.80989
GSM780725Pertuzumab treated after 4 days (P1_2)391.16490
GSM780726Pertuzumab treated after 4 days (P2_2)351.8789
GSM780727Pertuzumab treated after 4 days (P3_2)374.30389
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)266.19486
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)310.01988
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)295.62687
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)268.25286
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)313.28788